We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us

Download Mobile App




New Theory Casts Doubt on Role of MYC-Specific Target Genes in Cancer Development

By LabMedica International staff writers
Posted on 09 Oct 2012
Breaking away from long held theories of how the MYC oncogene functions in many different types of cancers, a recent study found that when overexpressed, the c-Myc protein attached to the promoters and enhancers of all active genes massively amplify the active genes' output of proteins and mRNA.

MYC (v-myc myelocytomatosis viral oncogene homolog protein) is a transcription factor that activates expression of a great number of genes through binding on consensus sequences and recruiting histone acetyltransferases (HATs). More...
By acting as a transcriptional repressor in normal cells, MYC has a direct role in the control of DNA replication.

The MYC protein (c-Myc) is a multifunctional, nuclear phosphoprotein that plays a role in cell cycle progression, apoptosis, and cellular transformation. It functions as a transcription factor that regulates transcription of specific target genes. Mutations, overexpression, rearrangement, and translocation of this gene have been associated with a variety of hematopoietic tumors, leukemias, and lymphomas, including Burkitt lymphoma.

The effect of high levels of c-Myc on global gene regulation has not been well understood but was widely thought to involve newly activated or repressed “Myc target genes.” Results reported in the September 28, 2012, issue of the journal Cell casts doubt on the existence of such Myc target genes.

Investigators at the Massachusetts Institute of Technology (Cambridge, MA, USA) working with cancer cell cultures and mouse cancer models developed a new explanation for c-Myc activity. They suggested that in tumor cells expressing high levels of c-Myc the transcription factor accumulated in the promoter regions of active genes and caused transcriptional amplification. This amplification produced increased levels of transcripts within the cell’s gene expression program.

Amplification of all active genes rather than binding and regulating a new set of genes provides an explanation for the diverse effects of oncogenic c-Myc on gene expression in different tumor cells and suggests that transcriptional amplification overpowers the molecular signals that normally prevent tumor cell growth and proliferation.

"MYC is a key driver in most major cancers, but it has been notoriously difficult to drug," said senior author Dr. Richard Young, professor of biology at the Massachusetts Institute of Technology. "Now that we know the mechanism by which c-Myc acts, we can go after the components of that mechanism as potential drug targets. This research creates an even stronger impetus to find a way to drug the thing."

Related Links:
Massachusetts Institute of Technology



Gold Member
Nucleic Acid Extractor System
NEOS-96 XT
Online QC Software
Acusera 24•7
New
Automated Coagulation Analyzer
Hemolumi H6
Repetitive Pipette
VWR® Stepper Pro
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Clinical Chemistry

view channel
Image: Characterization of EV separated by distinct methods (Photo courtesy of Yuanyuan Liu, Yanbin Guo et al. Engineering, doi.org/10.1016/j.eng.2025.12.009)

Liquid Biopsy Biomarkers May Improve Childhood Epilepsy Diagnosis

Childhood epilepsy remains a major neurological disorder with unmet needs for accurate, non-invasive biomarkers, as conventional tests such as electroencephalography and neuroimaging can have limited sensitivity... Read more

Molecular Diagnostics

view channel
Image: NeoCircle Study Synopsis (George, A.M., Chen, Y., Gladchuk, S. et al. EMBO Molecular Medicine (2026). DOI: 10.1038/s44321-026-00447-z)

Ultrasensitive MRD Blood Test Detects Early Breast Cancer Recurrence

SAGA Diagnostics (Morrisville, NC, USA), a company specializing in tumor-informed, blood-based cancer detection and precision medicine, announced the publication of a new study evaluating its Pathlight... Read more

Pathology

view channel
Image: Immune-related signals in routine bone marrow biopsy slides could help predict multiple myeloma outcomes and support more personalized treatment strategies (image credit: Shutterstock)

AI Tool Extracts Immune Signals from Biopsy to Inform Myeloma Therapy

Multiple myeloma is a bone marrow malignancy in which patients can respond very differently to the same treatments, making initial therapy decisions difficult. Clinicians must choose among options such... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.